20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Organ damage Mouse studies suggest inhibiting CDKN1A could help treat cardiac injury. In cardiac tissue from a neonatal mouse model of surgical resection-induced cardiac injury, levels of CDKN1A were lower in the regenerating myocardium than...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Kevetrin thioureidobutyronitrile: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in about 48 patients with advanced solid tumors showed that once-weekly 10-750 mg/m 2 IV Kevetrin given for the first 3 weeks of each 4-week cycle met the...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Cyclin-dependent kinase inhibitor 1A (p21, Cip1)(CDKN1A; CIP1) and ribosomal protein S6 (RPS6) as prognostic markers in head and neck squamous cell

BiomarkersRPS6Cyclin-dependent kinase inhibitor 1Ap21, Cip1CDKN1ACIP1ribosomal protein S6 (RPS6)Spanish National Cancer Research Centre (CNIO)...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

Cellceutix completed enrollment of >40 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle. Next half, the company plans to...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Thioureidobutyronitrile: Interim Phase I data

Interim data from 1 patient with stage IV thymoma in his eleventh month of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly IV Kevetrin for the first 3 weeks of a...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Trojantec, Sellas deal

Trojantec granted Sellas exclusive, worldwide rights to develop and commercialize TR-1 cancer therapeutic technology and corresponding therapeutics. Trojantec will receive an upfront payment and is eligible for clinical, regulatory and commercial milestones and royalties....
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Three-gene signature predictive of indolent prostate cancer A three-gene signature could help identify patients who...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Cizzle Biotechnology, Fujirebio deal

Cizzle and Fujirebio's Fujirebio Diagnostics Inc. will co-develop Cizzle's blood test that detects a variant of CDKN1A interacting zinc finger protein 1 (CIZ1) to diagnose early stage lung cancers. The companies will develop a...
08:00 , Feb 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer IL-20; IL-20 receptor-a (IL20R1; IL20RA); cyclin-dependent kinase inhibitor 1A (p21, Cip1)...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Plasma levels of the CDKN1A interacting zinc finger protein 1 (CIZ1) truncated variant to diagnose early stage lung cancer Patient...